Skip to main content

Advertisement

SpringerLink
Log in

Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the outcomes of a 6-month follow-up after switching to brolucizumab from aflibercept to treat neovascular age-related macular degeneration (AMD) in Japanese patients.

Study design

Retrospective observational study.

Methods

We studied 45 consecutive eyes of 42 patients diagnosed with neovascular AMD, who were switched to intravitreal brolucizumab injection (IVBr) after receiving intravitreal aflibercept injection (IVA) using a treat-and-extend (TAE) regimen. Patients who had brolucizumab-associated intraocular inflammation (IOI) were excluded from the study. The mean changes in the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), central foveal thickness (CFT), central choroidal thickness (CCT), and treatment intervals were evaluated at 6 months after the switch to IVBr.

Results

One eye of 1 patient was excluded because of IOI after the switch; 44 eyes of 41 patients were enrolled in this study. The mean logMAR BCVA was maintained throughout the follow-up period when compared with the baseline value (P > .05 at 6 months). However, the mean CFT and CCT at 6 months had decreased significantly (P < .05 and P < .001, respectively). The mean treatment interval was extended from 5.75 to 8.12 weeks.

Conclusion

Switching to brolucizumab from aflibercept using a TAE regimen might be effective for maintaining functional outcomes and extending intervals in Japanese patients with AMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

    Article  CAS  Google Scholar 

  2. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.

    Article  Google Scholar 

  3. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201.

    Article  Google Scholar 

  4. Hara C, Wakabayashi T, Nishida K. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69.

    Article  CAS  Google Scholar 

  5. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96:14–20.

    Article  Google Scholar 

  6. Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96:21–3.

    Article  Google Scholar 

  7. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.

    Article  Google Scholar 

  8. Bulirsch LM, Sassmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021;10:1136.

    Google Scholar 

  9. Haensli C, Pfister IB, Garweg JG. Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6 month outcomes. J Clin Med. 2021;10:2666.

    Article  CAS  Google Scholar 

  10. Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424–31.

    Article  Google Scholar 

  11. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156:23–8.e22.

    Article  CAS  Google Scholar 

  12. Mantel I, Gillies MC, Souied EH. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2018;63:638–45.

    Article  Google Scholar 

  13. Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, et al. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2020;104:493–9.

    Article  Google Scholar 

  14. Ying GS, Kim BJ, Maguire MG, Huang J, Daniel E, et al. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol. 2014;132:915–21.

    Article  Google Scholar 

  15. Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127:1345–59.

    Article  Google Scholar 

  16. Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Yokohama Sakae Kyosai Hospital, Yokohama, Japan

    Yoko Kitajima

  2. Department of Ophthalmology, Yokohama City University Medical Center, 57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan

    Maiko Maruyama-Inoue, Shoko Ikeda, Arisa Ito, Tatsuya Inoue, Yasuo Yanagi & Kazuaki Kadonosono

Authors
  1. Yoko Kitajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maiko Maruyama-Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shoko Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arisa Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tatsuya Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuo Yanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuaki Kadonosono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maiko Maruyama-Inoue.

Ethics declarations

Conflict of interest

Y. Kitajima, None; M. M-Inoue, None; S. Ikeda, None; A. Ito, None; T. Inoue, None; Y. Yanagi, None; K. Kadonosono, None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Maiko Maruyama-Inoue

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kitajima, Y., Maruyama-Inoue, M., Ikeda, S. et al. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol 66, 511–517 (2022). https://doi.org/10.1007/s10384-022-00940-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-022-00940-1

Keywords

Search

Navigation